Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Dozens injured in Russia after train crashes, overturns - 2Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- 3What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- 4IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- 5Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- Must-See Public Parks from Around the Globe
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Nitty gritty Manual for Picking Agreeable Tennis shoes
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- Two Passover initiatives target isolation and safety for Israel’s elderly
- Manual for Big name Work out schedules
- Kremlin: Russian troops conquer Pokrovsk after year of intense combat
- Multi-million-euro win in Spanish lottery in doubt due to oversight
